Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

More:
Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation